trial

Memantine Augmentation of Targeted Cognitive Training in Schizophrenia

NCTId NCT04857983
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 62 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2025-03-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
62 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2021-07-06
Primary completion
2025-03-30
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Memantine

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Sites

1 total
San Diego, United States

Linked catalysts

1
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia — primary completion2025-03-30

Facts & assertions

4 sourced
Enrollment
62
Phase
PHASE2,PHASE3
Primary Completion Date
2025-03-30
Status
COMPLETED
relationships
The graph out of here
drug
Memantine
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication